Comparative Pharmacology
Head-to-head clinical analysis: ATARAX versus CLARINEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATARAX versus CLARINEX.
ATARAX vs CLARINEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. It inhibits histamine release from mast cells and reduces allergic inflammation.
25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.
5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly, hepatic impairment, or renal insufficiency (up to 30-40 hours); steady-state achieved within 3-4 days.
Terminal elimination half-life is approximately 27 hours (range 20-30 hours). This long half-life supports once-daily dosing and allows for steady-state concentrations within 7 days.
Primarily hepatic metabolism via CYP3A4 and CYP2D6; renal excretion of metabolites accounts for approximately 70-80% of the dose, with less than 1% excreted unchanged; fecal excretion is about 10-15%.
Desloratadine is primarily eliminated via renal excretion (~40% as metabolites) and fecal elimination (~45% as metabolites). Less than 2% is excreted unchanged in urine.
Category C
Category C
Antihistamine
Antihistamine